Dan Boeglin is a corporate and transactional lawyer with deep experience in the life sciences industry. He has been lead counsel in more than 100 strategic transactions, including domestic and international acquisitions, divestitures, licensing, distribution, collaboration, research and development, and other complex matters for clients such as Zimmer Biomet, Baxter Healthcare, and Eli Lilly and Company.
In a complementary facet of his practice, Dan supports the boards of directors and senior management teams of companies in the biotechnology and medical device industries. To serve these clients, Dan combines his legal background of more than 35 years with his industry experience of more than 20 years to provide legal advice informed by an appreciation of relevant business, clinical, regulatory and intellectual property strategies and considerations. In this outside general counsel role, Dan has assisted his clients in going public and raising capital, in-licensing and out-licensing technologies, developing their products, and exiting successfully.